When was T-Therapeutics founded?

T-Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is T-Therapeutics located?

T-Therapeutics is headquartered in Cambridge, United Kingdom.

Who is the current CEO of T-Therapeutics?

Allan Bradley of T-Therapeutics. They have also founded 2 companies.

How many employees does T-Therapeutics have?

As of May 31, 2026, the latest employee count at T-Therapeutics is 61.

Is T-Therapeutics a funded company?

T-Therapeutics is a funded company, having raised a total of $91.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 15, 2023.

When was the latest funding round of T-Therapeutics?

T-Therapeutics' latest funding was a $***** Series A round on Nov 13, 2025, with participation from 8 investors.

Where does T-Therapeutics rank among its competitors?

T-Therapeutics ranks 159th amongst 3296 active competitors, of which 1139 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was T-Therapeutics, which secured $32M in Nov, 2025.

Who are the top competitors of T-Therapeutics?

T-Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, T-Therapeutics secured the most recent funding round in November, 2025.

T-Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.

Website: t-therapeutics.com
Email ID: *****@t-therapeutics.com

Key Metrics

Founded Year

2022

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$91.4M in 2 rounds

Latest Funding Round

Series A, Nov 13, 2025, $*****

Investors

University of Cambridge & 7 more

Ranked

159^th among 3296 active competitors

Employee Count

61 as on May 31, 2026

Similar Companies

BeiGene & 789 more

View T-Therapeutics' full profile

T-Therapeutics has raised a total funding of $91.4M over 2 rounds. Its first funding round was on Nov 15, 2023. Its latest funding round was a Series A round on Nov 13, 2025 for $*****. 8 investors participated in its latest round. T-Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of T-Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2025	2161517	Series A	5982592	4753845	6052715	5717528
Nov 15, 2023	9802129	Series A	4579474	8438746	Sanofi Ventures & 5 more	8251166

Access funding benchmarks and valuations. Sign up today!

View details of T-Therapeutics's funding rounds and investors

The founders of T-Therapeutics are Allan Bradley and Haydn Prosser. Allan Bradley is the CEO of T-Therapeutics.

Here are the details of T-Therapeutics' key team members:

Allan Bradley: Co-Founder & CEO of T-Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Haydn Prosser: Co-Founder & Director of T-Therapeutics.

View details of T-Therapeutics's Founder profiles and Board Members

T-Therapeutics' employee count trend

T-Therapeutics has 61 employees as of May 26. Here is T-Therapeutics's employee count trend over the years:

Uncover T-Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T-Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of T-Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
159th	T-Therapeutics 2022, Cambridge (United Kingdom), Series A	Developer of T-cell-based rtherapeutics for cancer treatment	$91.4M	Sanofi Ventures, BGF & 6 others	61/100